Ayurvedic formulations were considered the best and safer alternatives for synthetic drugs. But the demand to such products is diminishing due to lack of standardization. Ashwagandharishtam, a fermented kind of ayurvedic formulation, is used to treat epilepsy, nervous disorders, skin diseases, immune disorders and rheumatism. In the present study, the standardization of Ashwagandharishtam using sophisticated techniques were attempted for assessing the quality and safety of herbal products involved in it. It was formulated according to a working formula and its physicochemical, pharmacological and biological parameters were determined. The results of physicochemical studies showed that the values were under acceptable limits as per the Ayurvedic Pharmacopoeial specifications. FTIR studies of formulation revealed the presence of functional groups similar to Ashwagandha powder. The heavy metal content in the formulation is determined using Atomic Absorption Spectroscopy. HPTLC reports proved the presence of biomarker, withanolide-A in ashwagandharishtam which helped in its chemical standardization. The anti-epileptic activity of ashwagandharishtamwas evaluated by Maximal electro shock (MES) method in rats. It exhibited a dose dependent significant (P<0.001) reduction in various phases of epileptic seizures when compared with that of standard phenytoin. It was also assessed for its anti inflammatory activity in carrageen induced paw edema method which showed a good activity comparable to standard thus making it biologically standardized.